Brian Armstrong’s NewLimit raises a $130M Series B, laying out road map for anti-aging drugs

Andrew Dunn

Senior Biopharma Correspondent

NewLimit, an anti-aging biotech startup backed by Coinbase CEO Brian Armstrong, has raised a $130 million Series B round to get its lead drug candidates …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Brian Armstrong’s NewLimit raises a $130M Series B, laying out road map for anti-aging drugs

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Controversial doctor Vinay Prasad named CBER director

Vertex pauses study of mRNA therapy for cystic fibrosis

Exclusive: Degradation startup raises $39M for pivot to PROTACs and clinical entry

Lilly to pay up to $415M in ALS deal; Actuate’s mid-stage pancreatic cancer data

Bristol Myers to lay off over 500 workers in New Jersey

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

Bri­an Arm­strong’s NewLim­it rais­es a $130M Se­ries B, lay­ing out road map for an­ti-ag­ing drugs

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Con­tro­ver­sial doc­tor Vinay Prasad named CBER di­rec­tor

Ver­tex paus­es study of mR­NA ther­a­py for cys­tic fi­bro­sis

Ex­clu­sive: Degra­da­tion start­up rais­es $39M for piv­ot to PRO­TACs and clin­i­cal en­try

Lil­ly to pay up to $415M in ALS deal; Ac­tu­ate’s mid-stage pan­cre­at­ic can­cer da­ta

Bris­tol My­ers to lay off over 500 work­ers in New Jer­sey

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

Brian Armstrong’s NewLimit raises a $130M Series B, laying out road map for anti-aging drugs

Controversial doctor Vinay Prasad named CBER director

Vertex pauses study of mRNA therapy for cystic fibrosis

Exclusive: Degradation startup raises $39M for pivot to PROTACs and clinical entry

Lilly to pay up to $415M in ALS deal; Actuate’s mid-stage pancreatic cancer data

Bristol Myers to lay off over 500 workers in New Jersey

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges